• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

D-色氨酸-6-促黄体生成素释放激素微胶囊缓释制剂诱导的治疗性性腺功能减退:8例子宫内膜异位症女性的初步研究

Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis.

作者信息

Zorn J R, Tanger C, Roger M, Grenier J, Comaru-Schally A M, Schally A V

机构信息

Clinique Universitaire Baudelocque, Paris, France.

出版信息

Int J Fertil. 1986 Mar-Apr;31(1):11-3, 16-27.

PMID:2908272
Abstract

Eight menstrually cycling women with proven endometriosis were treated with a delayed-release preparation of the superactive agonist D-Trp-6-LH-RH in biodegradable microcapsules, administered intramuscularly at intervals of 16 to 36 days for a period of 3 to 5 months. After the first injection which caused a transient stimulatory response, a sustained hypogonadal state, characterized by an estradiol (E2) level less than 50 pg/mL, was induced in all patients by day +14.7 (range 7.19). Subsequent injections caused no more stimulation, but a continuous decrease in E2 levels was observed. In all patients, E2 levels fell to zero after the second or third injection. Gonadotropins remained in the normal range throughout the course of treatment. Hot flashes and severe dyspareunia (related to vaginal dryness) were the main side effects. Resumption of normal pituitary-ovarian activity was documented in all patients after the last injection; the end of the hypogonadal state, ovulation and menses, occurred on days 41 (range 32-59), 58 (range 51-64) and 70 (range 65-76), respectively. All patients showed a clinical improvement. Our results demonstrate that a long-lasting, reversible hypogonadism can be induced in cyclic women by intramuscular injections of D-Trp-6-LH-RH microcapsules at monthly intervals. This simple and convenient treatment should be useful in treating endometriosis and other conditions.

摘要

八名经证实患有子宫内膜异位症的月经周期正常的女性,接受了可生物降解微胶囊包裹的超活性激动剂D-色氨酸-6-促黄体生成素释放激素(D-Trp-6-LH-RH)缓释制剂治疗,每16至36天肌肉注射一次,持续3至5个月。首次注射引起短暂的刺激反应后,到第14.7天(范围7.1 - 9天)时,所有患者均诱导出持续的性腺功能减退状态,其特征为雌二醇(E2)水平低于50 pg/mL。后续注射未再引起刺激,但观察到E2水平持续下降。所有患者在第二次或第三次注射后E2水平降至零。在整个治疗过程中促性腺激素水平保持在正常范围内。潮热和严重性交困难(与阴道干燥有关)是主要的副作用。最后一次注射后,所有患者均恢复了正常的垂体-卵巢活动;性腺功能减退状态结束、排卵和月经分别发生在第41天(范围32 - 59天)、第58天(范围51 - 64天)和第70天(范围65 - 76天)。所有患者临床症状均有改善。我们的结果表明,通过每月一次肌肉注射D-Trp-6-LH-RH微胶囊,可在月经周期正常的女性中诱导出持久、可逆的性腺功能减退。这种简单便捷的治疗方法在治疗子宫内膜异位症和其他病症方面应会有用。

相似文献

1
Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis.D-色氨酸-6-促黄体生成素释放激素微胶囊缓释制剂诱导的治疗性性腺功能减退:8例子宫内膜异位症女性的初步研究
Int J Fertil. 1986 Mar-Apr;31(1):11-3, 16-27.
2
Long-term use of an LH-RH agonist in the management of uterine leiomyomas: a study of 17 cases.
Int J Fertil. 1989 Jan-Feb;34(1):19-24.
3
Monthly administration of the LH-RH analogue decapeptyl for long-term treatment of ovarian dysfunctions and estrogen-dependent disorders.每月注射促性腺激素释放激素类似物(十肽)以长期治疗卵巢功能障碍和雌激素依赖性疾病。
Int J Fertil. 1989 Jul-Aug;34(4):262-70.
4
Medical reversible castration with D-Trp-6-LH-RH microcapsules for the treatment of endometriosis. Preliminary results in a series of 51 patients.使用D-色氨酸-6-促黄体生成素释放激素微胶囊进行医学可逆性去势治疗子宫内膜异位症。51例患者的初步结果。
Contrib Gynecol Obstet. 1987;16:254-9.
5
One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats.一种用于治疗大鼠实验性子宫内膜异位症的促黄体生成素释放激素激动剂(醋酸亮丙瑞林)的1个月释放型注射用微胶囊。
J Pharmacol Exp Ther. 1988 Feb;244(2):744-50.
6
Studies of a controlled-release microcapsule formulation of an LH-RH agonist (D-Trp-6-LH-RH) in the rhesus monkey menstrual cycle.恒河猴月经周期中促黄体生成激素释放激素激动剂(D-色氨酸-6-促黄体生成激素释放激素)控释微胶囊制剂的研究。
Int J Fertil. 1985;30(2):19-26.
7
Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: long-term follow-up in a series of 50 patients.
Fertil Steril. 1990 Mar;53(3):401-6. doi: 10.1016/s0015-0282(16)53330-5.
8
Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis.促性腺激素释放激素激动剂与延长给药间隔方案治疗子宫腺肌病和子宫内膜异位症患者的疗效。
Gynecol Obstet Invest. 2010;69(2):73-7. doi: 10.1159/000258683. Epub 2009 Nov 17.
9
Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis.曲普瑞林3个月和28天制剂在子宫内膜异位症女性中实现和维持药物去势方面的等效性。
Fertil Steril. 2004 Feb;81(2):297-304. doi: 10.1016/j.fertnstert.2003.07.013.
10
Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.在正常男性中间歇性长期给予强效促性腺激素释放激素激动剂。
Int J Fertil. 1982;27(4):234-7.

引用本文的文献

1
Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.长效促黄体生成素释放激素激动剂递送系统与米托蒽醌化疗联合应用:在大鼠前列腺癌模型中疗效增强。
Proc Natl Acad Sci U S A. 1986 Nov;83(22):8764-8. doi: 10.1073/pnas.83.22.8764.